Company Name : Intas Pharma Ltd
Address : Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad – 380009, Gujarat, India
Tel No: 91 79 6652 3100 / 2657 6655
Email : generalqueries@intaspharma.com, productqueries@intaspharma.com
Website : http://www.intaspharma.com/
Company Profile
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India.
Intas’ success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R & D, Biotechnology and global operations over three decades. As of 31st of March 2013, Intas has grown to be a ~$650 million* organization with a revenue growth over 30% CAGR over the last 5 years and a profit growth of ~50% CAGR over the same period. Intas is now ranked as the 12th largest pharmaceutical company in the domestic market (as per IMS Health India, Secondary Stockist Audit (SSA), April, 2014 MAT).
In the domestic market, Intas is the 5th largest corporate in Indian Chronic Pharma Market with a market share of 4.85%. It also has presence in cardiovascular system (CVS), diabetology, gynecology, infertility, respiratory care, gastroenterology, pain management as well as other therapeutic segments.
Besides rapidly growing domestic prominence, Intas is also present in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, Asia – Pacific as well as CIS and MENA countries.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…